DGX as reported
Quest Diagnostics reported $11.3B of revenue over the trailing twelve months, +11% on the year before. 11 reported series are charted on this page, each one as filed.
$11.3B
Revenue, trailing twelve months · to Q1 2026 · +11% against the twelve months before
- Net Income
- $1.02B
Net Income · +14% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $1.33B
Free Cash Flow · +26% year on year · trailing twelve months to Q1 2026
- Op Margin
- 14%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $11.3B | +11% | Q1 2026 |
| Net Income | $1.02B | +14% | Q1 2026 |
| EPS | $9.05 | +14% | Q1 2026 |
| Gross Margin | 33% | n/a | Q1 2026 |
| Op Margin | 14% | n/a | Q1 2026 |
| Net Margin | 9.1% | n/a | Q1 2026 |
| ROE | 14% | n/a | Q1 2026 |
| ROA | 6.0% | n/a | Q1 2026 |
| ROIC | 9.7% | n/a | Q1 2026 |
| Free Cash Flow | $1.33B | +26% | Q1 2026 |
| P/E | 27.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Quest Diagnostics (DGX) - Revenue & ProfitRevenue & ProfitQuest Diagnostics (DGX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #24 of 29 by Smart Score